ARQT

Arcutis Biotherapeutics, Inc. (ARQT) | Rumor.io

Arcutis Biotherapeutics

ARQT

Attention (50-day avg)0%

Attention rank (50-day avg)#2,195

Bullish sentiment (50-day avg)90%

Price to earnings ratio122.4

Market capitalization3.4B

Earnings per share0.22

Dividend yield (TTM)—

Revenue (annual)376.1M

Net income (annual)-16.1M

Social

What share of all stock conversation is about ARQT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 16

$ARQT stock price increased by +11.3% on September 16, finishing at the daily high with strength maintained through the last hour.
Arcutis Biotherapeutics' management is participating in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.
Some analysts believe $ARQT will reach $30 before the next earnings report (end of October), and the stock is being added to the S&P 600 small cap index at the next rebalance.

Generated by AI

Sentiment

Of the messages about ARQT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +40	94.29% +7.75	93.36% +3.67
Bearish	0% 0	0% -40	5.71% -7.75	6.64% -3.67

Bullish· Oct 29

Arcutis Biotherapeutics' Q3 earnings beat expectations, with a strong topline beat and profitability, and the company has provided above-consensus 2026 guidance.
Analysts are upbeat about the company's prospects, with multiple firms upgrading their price targets, including Mizuho, Morgan Stanley, and H.C. Wainwright, and Jefferies and TD Cowen also raising their targets.
The company's revenue is expected to see significant growth, with the US and Canada being just the beginning, and the EU, Japan, and China still untapped, potentially leading to substantial upside.

Bearish· Aug 15

The market is crowded for Arcutis Biotherapeutics' products, potentially reducing their competitiveness in the AD and PsO markets.
The company's slowing metrics for seb derm, despite initial patient enthusiasm, are a cause for concern among bears.
Arcutis Biotherapeutics' high short interest (19%) and recent price decline despite positive earnings and guidance suggest that investors are losing confidence in the stock.

Generated by AI

Topics

Of the messages about ARQT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	20%	48.39%
Technical Analysis	—	—	80%	43.12%
Analysts	—	—	0%	4.98%
Earnings	—	—	0%	3.02%
Controversies	—	—	0%	0.49%
Macro	—	—	0%	0%

Dec 18

The FDA has approved Arcutis Biotherapeutics' ZORYVE (Roflumilast foam 0.3%) for the treatment of seborrheic dermatitis.
ZORYVE is the first drug approved for seborrheic dermatitis with a new mechanism of action (MOA) in over two decades.
Arcutis Biotherapeutics' stock price surged 34.8% premarket after the FDA approval, and the company's shares rallied 28% in wake of the news.

Generated by AI

Community

Of the messages about ARQT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	5.56%	66.9%	70.84%
Newcomers	100%	94.44%	33.1%	29.16%

Regulars· Oct 28

* $ARQT's Q3 report shows a 122% YoY revenue growth, driven by the broad adoption of ZORYVE cream for pediatric atopic dermatitis, with sales guidance of $455-$470M for 2026 and a projected peak run rate.
* The company's Q3 revenue reached $99.219M, exceeding consensus estimates of $86.98M, and the EPS came in at 6c, also beating consensus estimates.
* Arcutis Biotherapeutics' third-quarter financial results demonstrate a strong sequential growth of 22% over Q2, and the company is on track to reach a $500M run rate.

Newcomers· Oct 29

Newcomers are focused on the recent earnings report, with Arcutis Biotherapeutics posting its first-ever profit and ZORYVE sales exploding to $99.2M, up 122% YoY.
The company's guidance for 2026 is seen as a positive catalyst, with sales expected to reach $455M-$470M, beating estimates.
Many newcomers are considering buying the stock, citing its relatively low price point and strong technical indicators, such as the MACD golden cross and bullish alignment.

Generated by AI

News

Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares

11d agoInvesting.com

Arcutis Biotherapeutics director Welgus sells $114k in shares

12d agoInvesting.com

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

12d agofinance.yahoo.com

Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%

Key TakeawaysConference Pop: Arcutis Biotherapeutics stock jumped 11. 19% on September 16, closing at $26.

13d agofinance.yahoo.com

Arcutis at Morgan Stanley conference: zoryve drives growth push

13d agoInvesting.com

Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock

19d agoInvesting.com

Also Discussed

Investors talking about ARQT also mention

#	Name	Attention
1	IGMS - IGM Biosciences, Inc.	——
2	SWTX - SpringWorks Therapeutics, Inc.	——
3	DAWN - Day One Biopharmaceuticals, Inc.	——
4	C4 Therapeutics IncCCCC	0.01%new
5	Aquestive Therapeutics Inc.AQST	0%+0
6	Shattuck Labs, Inc.STTK	0%new
7	Coherus Oncology, Inc.CHRS	0%0
8	Crinetics Pharmaceuticals IncCRNX	0%0
9	Ars Pharmaceuticals IncSPRY	0%0
10	Verrica Pharmaceuticals Inc.VRCA	0%0

Arcutis Biotherapeutics, Inc.

Healthcare
Biotechnology

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases. The company’s portfolio centers on ZORYVE, a branded treatment platform that includes topical formulations used in conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis in sensitive areas. Arcutis also advances a pipeline of dermatology candidates, including additional topical and systemic programs designed to address inflammatory skin disorders with high unmet medical need. Its research and development approach combines dermatology expertise with targeted drug development against biologically validated pathways, positioning the company as a specialist player in the medical dermatology market. Based in Westlake Village, California, Arcutis Biotherapeutics serves patients, dermatology clinicians, and healthcare providers through prescription therapies aimed at chronic skin conditions.

Website

Location

3027 Townsgate Road

Westlake Village, CA, 91361

United States

Social

What share of all stock conversation is about ARQT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% 0

Sep 16

$ARQT stock price increased by +11.3% on September 16, finishing at the daily high with strength maintained through the last hour.
Arcutis Biotherapeutics' management is participating in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16.
Some analysts believe $ARQT will reach $30 before the next earnings report (end of October), and the stock is being added to the S&P 600 small cap index at the next rebalance.

Generated by AI

Sentiment

Of the messages about ARQT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	100% +40	94.29% +7.75	93.36% +3.67
Bearish	0% 0	0% -40	5.71% -7.75	6.64% -3.67

Bullish· Oct 29

Arcutis Biotherapeutics' Q3 earnings beat expectations, with a strong topline beat and profitability, and the company has provided above-consensus 2026 guidance.
Analysts are upbeat about the company's prospects, with multiple firms upgrading their price targets, including Mizuho, Morgan Stanley, and H.C. Wainwright, and Jefferies and TD Cowen also raising their targets.
The company's revenue is expected to see significant growth, with the US and Canada being just the beginning, and the EU, Japan, and China still untapped, potentially leading to substantial upside.

Bearish· Aug 15

The market is crowded for Arcutis Biotherapeutics' products, potentially reducing their competitiveness in the AD and PsO markets.
The company's slowing metrics for seb derm, despite initial patient enthusiasm, are a cause for concern among bears.
Arcutis Biotherapeutics' high short interest (19%) and recent price decline despite positive earnings and guidance suggest that investors are losing confidence in the stock.

Generated by AI

Topics

Of the messages about ARQT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	20%	48.39%
Technical Analysis	—	—	80%	43.12%
Analysts	—	—	0%	4.98%
Earnings	—	—	0%	3.02%
Controversies	—	—	0%	0.49%
Macro	—	—	0%	0%

Dec 18

The FDA has approved Arcutis Biotherapeutics' ZORYVE (Roflumilast foam 0.3%) for the treatment of seborrheic dermatitis.
ZORYVE is the first drug approved for seborrheic dermatitis with a new mechanism of action (MOA) in over two decades.
Arcutis Biotherapeutics' stock price surged 34.8% premarket after the FDA approval, and the company's shares rallied 28% in wake of the news.

Generated by AI

Community

Of the messages about ARQT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	5.56%	66.9%	70.84%
Newcomers	100%	94.44%	33.1%	29.16%

Regulars· Oct 28

* $ARQT's Q3 report shows a 122% YoY revenue growth, driven by the broad adoption of ZORYVE cream for pediatric atopic dermatitis, with sales guidance of $455-$470M for 2026 and a projected peak run rate.
* The company's Q3 revenue reached $99.219M, exceeding consensus estimates of $86.98M, and the EPS came in at 6c, also beating consensus estimates.
* Arcutis Biotherapeutics' third-quarter financial results demonstrate a strong sequential growth of 22% over Q2, and the company is on track to reach a $500M run rate.

Newcomers· Oct 29

Newcomers are focused on the recent earnings report, with Arcutis Biotherapeutics posting its first-ever profit and ZORYVE sales exploding to $99.2M, up 122% YoY.
The company's guidance for 2026 is seen as a positive catalyst, with sales expected to reach $455M-$470M, beating estimates.
Many newcomers are considering buying the stock, citing its relatively low price point and strong technical indicators, such as the MACD golden cross and bullish alignment.

Generated by AI

Arcutis Biotherapeutics

Social

Sep 16

Bullish· Oct 29

Bearish· Aug 15

Dec 18

Regulars· Oct 28

Newcomers· Oct 29

Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares

Arcutis Biotherapeutics director Welgus sells $114k in shares

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%

Arcutis at Morgan Stanley conference: zoryve drives growth push

Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock

Also Discussed

Arcutis Biotherapeutics, Inc.

Company Information

Location

Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares

Arcutis Biotherapeutics director Welgus sells $114k in shares

Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?

Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%

Arcutis at Morgan Stanley conference: zoryve drives growth push

Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock

Also Discussed

Social

Sep 16

Bullish· Oct 29

Bearish· Aug 15

Dec 18

Regulars· Oct 28

Newcomers· Oct 29